Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06181786
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-26
First Post:
2023-12-13
Brief Title:
A Study of IMB-101 in Healthy Volunteers and Participants With Rheumatoid Arthritis
Sponsor:
IMBiologics Corp
Organization:
IMBiologics Corp
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Single and Multiple Ascending Dose Phase 1 Clinical Trial to Evaluate Safety Tolerability Pharmacokinetics and Pharmacodynamics of IMB-101 in Healthy Volunteers and Patients With Active Rheumatoid Arthritis RA
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate the safety and tolerability of intravenous IV doses of IMB-101 in healthy volunteers and participants with active RA on a stable regimen of methotrexate
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None